John M. Pagel, MD, PhD, on Polatuzumab Vedotin

The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting& Exposition.

Source: CancerNetwork - December 13, 2019 Category: Cancer & Oncology Authors: John M. Pagel, MD, PhD Source Type: news